Your logo

Prostate News Archive


  • New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer (EurekAlert!)

    A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows.

  • Spectrum requests approval of prostate cancer therapy (Pharmaceutical Business Review)

    Spectrum Pharmaceuticals has filed its new drug application to US regulators for satraplatin, its drug candidate for the treatment of hormone refractory prostate cancer for those who have failed chemotherapy.

  • OHSU Cancer Institute Researcher Finds Drug Combination Helps Halt Prostate Cancer (RedNova)

    A high-dose activated vitamin D pill combined with docetaxel, a chemotherapy drug, extends the lives of men with advanced prostate cancer.

  • Back to Prostate News Archive